Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Summary
The study aim to investigate the relationship between cutaneous adverse events and quality of life in patients taking immune check point inhibitor or cyclin-dependent kinase (CDK) 4 and 6 inhibitors by two steps. In the first one, it will be investigated the relationship between the skin toxicity related to the use selected therapies and the quality of life of patients already receiving these therapies for treatment of their cancer. In the second one, it will be evaluated the relationship between skin toxicity and quality of life over three months of treatment in patients initially naïve for selected therapies. Cancer included in the analysis are NSCLC, renal cancer, gastric cancer, breast cancer, bladder cancer, melanoma, squamous cell carcinoma of the head and neck.
Official title: Evaluation of Skin Health and Quality of Life in Patients Receiving Anticancer Therapies Based on Monoclonal Antibody Anti-PD1/PDL1/CTLA4 or Cyclin-dependent Kinase (CDK) Inhibitors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
420
Start Date
2023-05-22
Completion Date
2025-09-22
Last Updated
2024-10-04
Healthy Volunteers
No
Conditions
Interventions
EQ-5D-5L questionnaire
Quality of life evaluation questionnaire
FACT-G (Functional Assessment of Cancer Therapy - General)
Quality of life evaluation questionnaire
FACT-EGFRI-18 (Functional Assessment of Cancer Therapy - Epidermal Growth Factor Inhibitors 18 Item)
Self reported evaluation of cutaneous toxicity questionnaire.
Locations (1)
Roberto Iacovelli
Roma, Italy